PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components

Poly(ADP-ribose) polymerase inhibitors (PARPi) have been in clinical use since 2014 for certain patients with germline BRCA1/2 mutations, but as evidence and approvals for their use in a wider range of patients grow, the question of how best to identify patients who would benefit from PARPi becomes...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Sullivan Coyne, Geraldine, Karlovich, Chris, Wilsker, Deborah, Voth, Andrea Regier, Parchment, Ralph E, Chen, Alice P, Doroshow, James H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885121/
https://www.ncbi.nlm.nih.gov/pubmed/35237050
http://dx.doi.org/10.2147/OTT.S278092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885121/
https://www.ncbi.nlm.nih.gov/pubmed/35237050
http://dx.doi.org/10.2147/OTT.S278092

Ejemplares similares